181 related articles for article (PubMed ID: 31141195)
21. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
Staszewski S; Keiser P; Montaner J; Raffi F; Gathe J; Brotas V; Hicks C; Hammer SM; Cooper D; Johnson M; Tortell S; Cutrell A; Thorborn D; Isaacs R; Hetherington S; Steel H; Spreen W;
JAMA; 2001 Mar; 285(9):1155-63. PubMed ID: 11231744
[TBL] [Abstract][Full Text] [Related]
22. Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients.
Bouazza N; Cressey TR; Foissac F; Bienczak A; Denti P; McIlleron H; Burger D; Penazzato M; Lallemant M; Capparelli EV; Treluyer JM; Urien S
J Antimicrob Chemother; 2017 Feb; 72(2):490-495. PubMed ID: 27798221
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naive patients.
Curran A; Rojas J; Cabello A; Troya J; Imaz A; Domingo P; Martinez E; Ryan P; Górgolas M; Podzamczer D; Knobel H; Gutiérrez F; Ribera E
J Antimicrob Chemother; 2016 Dec; 71(12):3510-3514. PubMed ID: 27591292
[TBL] [Abstract][Full Text] [Related]
24. Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.
Mulenga V; Musiime V; Kekitiinwa A; Cook AD; Abongomera G; Kenny J; Chabala C; Mirembe G; Asiimwe A; Owen-Powell E; Burger D; McIlleron H; Klein N; Chintu C; Thomason MJ; Kityo C; Walker AS; Gibb DM;
Lancet Infect Dis; 2016 Feb; 16(2):169-79. PubMed ID: 26481928
[TBL] [Abstract][Full Text] [Related]
25. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
Manfredi R; Calza L
AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
[TBL] [Abstract][Full Text] [Related]
26. Abacavir pharmacokinetics in human immunodeficiency virus-infected children ranging in age from 1 month to 16 years: a population analysis.
Jullien V; Urien S; Chappuy H; Dimet J; Rey E; Pons G; Blanche S; Tréluyer JM
J Clin Pharmacol; 2005 Mar; 45(3):257-64. PubMed ID: 15703361
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Abacavir/Dolutegravir/Lamivudine Combination Tablets in Healthy Japanese Study Participants.
Singh RP; Adkison K; Wolstenholme A; Hopking J; Wynne B
Clin Pharmacol Drug Dev; 2021 Sep; 10(9):985-993. PubMed ID: 34265164
[TBL] [Abstract][Full Text] [Related]
28. Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial.
Paediatric European Network for Treatment of AIDS (PENTA)
Lancet; 2002 Mar; 359(9308):733-40. PubMed ID: 11888583
[TBL] [Abstract][Full Text] [Related]
29. A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects.
Staszewski S; Katlama C; Harrer T; Massip P; Yeni P; Cutrell A; Tortell SM; Harrigan RP; Steel H; Lanier RE; Pearce G
AIDS; 1998 Nov; 12(16):F197-202. PubMed ID: 9833847
[TBL] [Abstract][Full Text] [Related]
30. Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients.
Jullien V; Tréluyer JM; Chappuy H; Dimet J; Rey E; Dupin N; Salmon D; Pons G; Urien S
Br J Clin Pharmacol; 2005 Feb; 59(2):183-8. PubMed ID: 15676040
[TBL] [Abstract][Full Text] [Related]
31. Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL).
Sosa N; Hill-Zabala C; Dejesus E; Herrera G; Florance A; Watson M; Vavro C; Shaefer M
J Acquir Immune Defic Syndr; 2005 Dec; 40(4):422-7. PubMed ID: 16280696
[TBL] [Abstract][Full Text] [Related]
32. Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial.
Winston A; Post FA; DeJesus E; Podzamczer D; Di Perri G; Estrada V; Raffi F; Ruane P; Peyrani P; Crofoot G; Mallon PWG; Castelli F; Yan M; Cox S; Das M; Cheng A; Rhee MS
Lancet HIV; 2018 Apr; 5(4):e162-e171. PubMed ID: 29475804
[TBL] [Abstract][Full Text] [Related]
33. Lamivudine/zidovudine/abacavir: triple combination tablet.
Ibbotson T; Perry CM
Drugs; 2003; 63(11):1089-98; discussion 1099-1100. PubMed ID: 12749741
[TBL] [Abstract][Full Text] [Related]
34. A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team.
Sáez-Llorens X; Nelson RP; Emmanuel P; Wiznia A; Mitchell C; Church JA; Sleasman J; Van Dyke R; Richardson CG; Cutrell A; Spreen W; Hetherington S
Pediatrics; 2001 Jan; 107(1):E4. PubMed ID: 11134468
[TBL] [Abstract][Full Text] [Related]
35. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction.
Martínez E; Larrousse M; Podzamczer D; Pérez I; Gutiérrez F; Loncá M; Barragán P; Deulofeu R; Casamitjana R; Mallolas J; Pich J; Gatell JM;
AIDS; 2010 Jan; 24(3):F1-9. PubMed ID: 20009917
[TBL] [Abstract][Full Text] [Related]
36. Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa.
Palmer M; Chersich M; Moultrie H; Kuhn L; Fairlie L; Meyers T
AIDS; 2013 Mar; 27(5):781-5. PubMed ID: 23169331
[TBL] [Abstract][Full Text] [Related]
37. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
[TBL] [Abstract][Full Text] [Related]
38. Effects of Low- and High-Mineral Content Water on the Relative Bioavailability of a Coformulated Abacavir/Dolutegravir/Lamivudine Dispersible Tablet in Healthy Adults.
Singh RP; Shaik JSB; Skoura N; Joshi S; Shreeves T; Casillas L; Buchanan AM
J Acquir Immune Defic Syndr; 2018 Dec; 79(5):631-638. PubMed ID: 30239425
[TBL] [Abstract][Full Text] [Related]
39. Lopinavir/ritonavir plus lamivudine and abacavir or zidovudine dose ratios for paediatric fixed-dose combinations.
Bouazza N; Foissac F; Fauchet F; Burger D; Kiechel JR; Treluyer JM; Capparelli EV; Lallemant M; Urien S
Antivir Ther; 2015; 20(2):225-33. PubMed ID: 25279808
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and Safety of Zidovudine, Lamivudine, and Lopinavir/Ritonavir in HIV-infected Children With Severe Acute Malnutrition in Sub-Saharan Africa: IMPAACT Protocol P1092.
Owor M; Tierney C; Ziemba L; Browning R; Moye J; Graham B; Reding C; Costello D; Norman J; Wiesner L; Hughes E; Whalen ME; Purdue L; Mmbaga BT; Kamthunzi P; Kawalazira R; Nathoo K; Bradford S; Coletti A; Aweeka F; Musoke P
Pediatr Infect Dis J; 2021 May; 40(5):446-452. PubMed ID: 33464021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
